Combining multi-modality brain data for disease diagnosis commonly leads to improved performance. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
We also assessed the rates in patients with other significant medical, neurologic, or mental comorbid illness. 3 key findings →
Design: cross-sectional Participants: 652,378 Evidence: low
Full summary, score breakdown and related studies → Original source
Underclassification of dementia from claims records can be partially remedied by increasing the period during which claims are compiled, but additional diagnostic sources will likely be needed to increase prevalence counts closer to 100% of true cases. 2 key findings →
Design: prospective cohort Participants: 4,166 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study demonstrates that influenza vaccination is associated with reduced AD risk in a nationwide sample of US adults aged 65 and older. 2 key findings →
Participants: 2,356,479 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The associations with vascular dementia may be one component of a broader association between autoimmune diseases and vascular damage. 5 key findings →
Design: cohort study Participants: 827 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Receiving two types of vaccinations versus one type was associated with lower dementia risk. 5 key findings →
Participants: 80,070 Evidence: moderate
Full summary, score breakdown and related studies → Original source
However, the credibility of these estimates is limited by the methodological quality of studies, primarily resulting from insufficient blinding of researchers interpreting the reference test. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
A cognitive symptom measure identified in discharge notes facilitated stratification of risk for dementia up to 8 years before diagnosis. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
ObjectivesIdentifying modifiable factors that shape cognitive aging trajectories is a central goal in aging research. 5 key findings →
Design: cross-sectional Participants: 4,140 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Atrial fibrillation (AF) is the most common clinical arrhythmia with substantial health and socioeconomic impact on healthcare.1 The number of people affected by this condition was estimated to be 33.5 million in 2010, with an increasing prevalence and incidence over the coming years.2 In 2017, there were 37.6 million [95% confidence interval (CI): 32.5–42.6 million] individuals with AF/atrial flutter globally.3 The estimated number of subjects with AF in 2030 in Europe will be 14–17 million, and the number of new cases of AF per year at 120 000–215 000.4 Atrial fibrillation is independently associated with increased mortality and morbidity from complications such as ischaemic stroke, dementia, and cognitive dysfunction.5 Oral anticoagulation can significantly reduce the risk of stroke, dementia, and death.6 As a part of a holistic or integrated approach to AF care, it is associated with improved outcomes7–9 and is advocated in guidelines.10,11 In many patients, AF can be asymptomatic, and the diagnosis is established after the appearance of a complication typically associated with AF, such as ischaemic stroke/systemic embolic or heart failure. 5 key findings →
Participants: 280 Evidence: high
Full summary, score breakdown and related studies → Original source
This study provides the first active comparator data on amyloid plaque clearance in patients with early symptomatic AD. 2 key findings →
Design: clinical trial Participants: 148 Evidence: high
Full summary, score breakdown and related studies → Original source
The pooled trial included 88,381 participants who received prescriptions for GLP-1 agonists (n = 12,351), DPP-4 inhibitors (n = 43,850), or sulfonylureas (n = 32,216) at baseline and were followed for an average of 4.3 years. 5 key findings →
Participants: 12,351 Evidence: low
Full summary, score breakdown and related studies → Original source
Therefore, respective software was developed in-house.8,9 Segmentation results are then analysed for potential associations with disease risks and to establish reference intervals of organ size and function.10 SHIP is also used as a basis for meta-research with a particular focus on incidental MRI findings and their effects on study participants.11,12 With its large amount of standardized data and the option to internally replicate findings from SHIP-START using data of the independent SHIP-TREND, the project offers good opportunities to apply new bioinformatical tools to mine the data and gain new insights into risk factors and pathomechanisms. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The study has been harmonized with leading international research so as to ensure adoption of best practice and comparability of results. 3 key findings →
Design: cohort study Participants: 25 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The development of Alzheimer's disease (AD) later in life may be reflective of environmental factors operating over the course of a lifetime. 3 key findings →
Design: case-control study Participants: 193 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher adherence to the MeDi was associated with lower risk for AD (odds ratio, 0.76; 95% confidence interval, 0.67-0.87; P<.001). 5 key findings →
Design: case-control study Participants: 194 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Current knowledge of cognitive dysfunction in Parkinson's disease (PD) has largely been obtained from studies of chronically treated patients in whom effects of disease chronicity, treatment, depression and dementia are confounding factors. 1 key finding →
Design: longitudinal study Participants: 60 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Growing evidence has linked long-term fine particulate matter (PM 2.5 ) exposure to neurological disorders. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
n d e n c e Changes in the Place of Death in the United States To the Editor: Where people die is an impor tant determinant of patient and caregiver expe rience.
Participants: 905,874 Evidence: low
Full summary, score breakdown and related studies → Original source
Global implementation of blood tests for Alzheimer's disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. 4 key findings →
Participants: 337 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These analyses provide preliminary support for IICV as a marker of incident AD and MCI. 4 key findings →
Design: longitudinal study Participants: 105 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Most investigations have previously focused on highly selected cohorts with established AD-endophenotypes (CSF biomarkers, autopsy report, PET etc.), while data on cohorts with clinical assessment are currently lacking, especially in non-European populations. 2 key findings →
Participants: 234 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We investigated plasma phosphorylated tau217 (p-tau217) and p-tau181 efficacy in predicting positive amyloid positron emission tomography (PET) results and cognitive stage transitions. 2 key findings →
Participants: 121 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's Disease (AD) is characterized by cognitive impairments that hinder daily activities and lead to personal and behavioral problems. 3 key findings →
Design: prospective cohort Participants: 41 Evidence: moderate
Full summary, score breakdown and related studies → Original source
62/100
The assessment of serum NfL and p-Tau 181 may provide a comprehensive view of FTLD, aiding in the differential diagnosis, in staging disease severity and in defining survival probability. 2 key findings →
Design: cross-sectional Participants: 417 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →